Lv21
118 积分 2025-09-23 加入
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers
2小时前
已完结
[Recommendations for diagnosis and treatment of systemic sclerosis in China]
7天前
已完结
[Standardized diagnosis and treatment of undifferentiated connective tissue disease and mixed connective tissue disease]
7天前
已完结
[Guideline for the diagnosis and treatment of non-radiographic axial spondyloarthritis (2024 edition)]
7天前
已完结
EULAR recommendations for the treatment of systemic sclerosis: 2023 update
7天前
已完结
[Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus (2025 edition)]
8天前
已完结
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies
2个月前
已完结
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
3个月前
已完结
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial
3个月前
已完结
Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease
3个月前
已关闭
皖公网安备34019202002308
